肌营养不良蛋白基因的遗传谱揭示了哥伦比亚肌营养不良病患者的新突变。

The Application of Clinical Genetics Pub Date : 2021-10-01 eCollection Date: 2021-01-01 DOI:10.2147/TACG.S317721
Paula Triana-Fonseca, Juan Fernando Parada-Márquez, Claudia T Silva-Aldana, Daniela Zambrano-Arenas, Laura Lucia Arias-Gomez, Natalia Morales-Fonseca, Esteban Medina-Méndez, Carlos M Restrepo, Daniel Felipe Silgado-Guzmán, Dora Janeth Fonseca-Mendoza
{"title":"肌营养不良蛋白基因的遗传谱揭示了哥伦比亚肌营养不良病患者的新突变。","authors":"Paula Triana-Fonseca,&nbsp;Juan Fernando Parada-Márquez,&nbsp;Claudia T Silva-Aldana,&nbsp;Daniela Zambrano-Arenas,&nbsp;Laura Lucia Arias-Gomez,&nbsp;Natalia Morales-Fonseca,&nbsp;Esteban Medina-Méndez,&nbsp;Carlos M Restrepo,&nbsp;Daniel Felipe Silgado-Guzmán,&nbsp;Dora Janeth Fonseca-Mendoza","doi":"10.2147/TACG.S317721","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common human dystrophinopathies with recessive X-linked inheritance. Dystrophin gene deletions and duplications are the most common mutations, followed by point mutations. The aim of this study is to characterize the mutational profile of the dystrophin gene in Colombian patients with DMD/BMD.</p><p><strong>Material and methods: </strong>Mutational profiling was determined in 69 affected patients using Sanger sequencing, next-generation sequencing (NGS) and/or multiplex ligation dependent-probes amplification (MLPA). Genetic variants were classified according to molecular consequence and new variants were determined through database and literature analysis.</p><p><strong>Results: </strong>Mutational profile in affected patients revealed that large deletions/duplications analyzed by MLPA accounted for 72.5% of all genetic variations. By using Sanger sequencing or NGS, we identified point mutations in 15.9% and small deletions in 11.6% of the patients. New mutations were found, most of them were point mutations or small deletions (10.1%).</p><p><strong>Conclusion: </strong>Our results described the genetic profile of the dystrophin gene in Colombian patients with DMD and contribute to efforts to identify molecular variants in Latin American populations. For our population, 18.8% of cases could be treated with FDA or MDA approved molecular therapies based on specific mutations. These data contribute to the establishment of appropriate genetic counseling and potential treatment.</p>","PeriodicalId":506374,"journal":{"name":"The Application of Clinical Genetics","volume":"14 ","pages":"399-408"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/96/tacg-14-399.PMC8493106.pdf","citationCount":"3","resultStr":"{\"title\":\"Genetic Profile of the Dystrophin Gene Reveals New Mutations in Colombian Patients Affected with Muscular Dystrophinopathy.\",\"authors\":\"Paula Triana-Fonseca,&nbsp;Juan Fernando Parada-Márquez,&nbsp;Claudia T Silva-Aldana,&nbsp;Daniela Zambrano-Arenas,&nbsp;Laura Lucia Arias-Gomez,&nbsp;Natalia Morales-Fonseca,&nbsp;Esteban Medina-Méndez,&nbsp;Carlos M Restrepo,&nbsp;Daniel Felipe Silgado-Guzmán,&nbsp;Dora Janeth Fonseca-Mendoza\",\"doi\":\"10.2147/TACG.S317721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common human dystrophinopathies with recessive X-linked inheritance. Dystrophin gene deletions and duplications are the most common mutations, followed by point mutations. The aim of this study is to characterize the mutational profile of the dystrophin gene in Colombian patients with DMD/BMD.</p><p><strong>Material and methods: </strong>Mutational profiling was determined in 69 affected patients using Sanger sequencing, next-generation sequencing (NGS) and/or multiplex ligation dependent-probes amplification (MLPA). Genetic variants were classified according to molecular consequence and new variants were determined through database and literature analysis.</p><p><strong>Results: </strong>Mutational profile in affected patients revealed that large deletions/duplications analyzed by MLPA accounted for 72.5% of all genetic variations. By using Sanger sequencing or NGS, we identified point mutations in 15.9% and small deletions in 11.6% of the patients. New mutations were found, most of them were point mutations or small deletions (10.1%).</p><p><strong>Conclusion: </strong>Our results described the genetic profile of the dystrophin gene in Colombian patients with DMD and contribute to efforts to identify molecular variants in Latin American populations. For our population, 18.8% of cases could be treated with FDA or MDA approved molecular therapies based on specific mutations. These data contribute to the establishment of appropriate genetic counseling and potential treatment.</p>\",\"PeriodicalId\":506374,\"journal\":{\"name\":\"The Application of Clinical Genetics\",\"volume\":\"14 \",\"pages\":\"399-408\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/96/tacg-14-399.PMC8493106.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Application of Clinical Genetics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/TACG.S317721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Application of Clinical Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/TACG.S317721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

背景:Duchenne和Becker肌营养不良症(DMD/BMD)是人类最常见的肌营养不良病,具有隐性x连锁遗传。肌营养不良蛋白基因缺失和重复是最常见的突变,其次是点突变。本研究的目的是表征哥伦比亚DMD/BMD患者的肌营养不良蛋白基因突变谱。材料和方法:使用Sanger测序、下一代测序(NGS)和/或多重连接依赖探针扩增(MLPA)对69名受影响患者进行突变谱分析。根据分子结果对遗传变异进行分类,并通过数据库和文献分析确定新的变异。结果:受影响患者的突变谱显示,MLPA分析的大缺失/重复占所有遗传变异的72.5%。通过Sanger测序或NGS,我们发现15.9%的患者存在点突变,11.6%的患者存在小缺失。发现新突变,以点突变或小缺失居多(10.1%)。结论:我们的研究结果描述了哥伦比亚DMD患者中肌营养不良蛋白基因的遗传谱,并有助于识别拉丁美洲人群中的分子变异。在我们的人群中,18.8%的病例可以用FDA或MDA批准的基于特定突变的分子疗法治疗。这些数据有助于建立适当的遗传咨询和潜在的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Genetic Profile of the Dystrophin Gene Reveals New Mutations in Colombian Patients Affected with Muscular Dystrophinopathy.

Genetic Profile of the Dystrophin Gene Reveals New Mutations in Colombian Patients Affected with Muscular Dystrophinopathy.

Background: Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common human dystrophinopathies with recessive X-linked inheritance. Dystrophin gene deletions and duplications are the most common mutations, followed by point mutations. The aim of this study is to characterize the mutational profile of the dystrophin gene in Colombian patients with DMD/BMD.

Material and methods: Mutational profiling was determined in 69 affected patients using Sanger sequencing, next-generation sequencing (NGS) and/or multiplex ligation dependent-probes amplification (MLPA). Genetic variants were classified according to molecular consequence and new variants were determined through database and literature analysis.

Results: Mutational profile in affected patients revealed that large deletions/duplications analyzed by MLPA accounted for 72.5% of all genetic variations. By using Sanger sequencing or NGS, we identified point mutations in 15.9% and small deletions in 11.6% of the patients. New mutations were found, most of them were point mutations or small deletions (10.1%).

Conclusion: Our results described the genetic profile of the dystrophin gene in Colombian patients with DMD and contribute to efforts to identify molecular variants in Latin American populations. For our population, 18.8% of cases could be treated with FDA or MDA approved molecular therapies based on specific mutations. These data contribute to the establishment of appropriate genetic counseling and potential treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书